metaPreg - Verapamil (versus unexposed) during pregnancy

Verapamil (versus unexposed)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.51 [1.01, 6.28]	-	1 study	39	56	not evaluable	ROB	4.46 [1.08; .]
3 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	2.69 [1.34, 5.44]	60%	2 studies	59	70	not evaluable	ROB	4.83 [2.00; .]
Low birth weight (< 2500g)	2.61 [1.58, 4.31]	-	1 study		18	not evaluable	ROB	4.66 [2.54; .]
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	1.76 [1.21, 2.55]	-	1 study		43	not evaluable	ROB	2.92 [1.72; .]
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study